821768-25-6Relevant articles and documents
Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2- yl)piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist
Swanson, Devin M.,Dubin, Adrienne E.,Shah, Chandra,Nasser, Nadia,Chang, Leon,Dax, Scott L.,Jetter, Michele,Breitenbucher, J. Guy,Liu, Changlu,Mazur, Curt,Lord, Brian,Gonzales, Lisa,Hoey, Kenway,Rizzolio, Michele,Bogenstaetter, Michael,Codd, Ellen E.,Lee, Doo H.,Zhang, Sui-Po,Chaplan, Sandra R.,Carruthers, Nicholas I.
, p. 1857 - 1872 (2005)
High throughput screening using the recombinant human TRPV1 receptor was used to identify a series of pyridinylpiperazine ureas (3) as TRPV1 vanilloid receptor ligands. Exploration of the structure-activity relationships by parallel synthesis identified t
SUBSTANCE FOR INHIBITION OF GLYCINE TRANSPORTER
-
Paragraph 0091-0093, (2020/04/21)
PROBLEM TO BE SOLVED: To provide a new compound or its pharmaceutically acceptable salt useful for preventing or treating diseases such as integrated dystonia, Alzheimer disease, cognitive dysfunction, dementia, anxiety disorder(such as global anxiety disorder, panic disorder, obsessive compulsive disorder, social anxiety disorder, post traumatic stress disorder, particular phobia, acute stress disorder), depression, drug dependence, convulsion, trembling, ache, Parkinson disease, attention-deficit/hyperactivity disorder, bipolar disorder, eating disorder or sleep disorder, based on inhibitory effect on glycine uptake. SOLUTION: There are provided a compound represented by the formula [I] or its pharmaceutically acceptable salt. COPYRIGHT: (C)2015,JPOandINPIT
FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF
-
Page/Page column 137, (2008/06/13)
-
